Search Results

Displaying Results 1-1 of 1 "'CLBR'"
Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.
Rheumatoid Arthritis Market to Surge by 2034 as Next-Generation Biologics and JAK Inhibitors Gain Traction | DelveInsight

Nov 05, 2025, 17:31 ET Rheumatoid Arthritis Market to Surge by 2034 as Next-Generation Biologics and JAK Inhibitors Gain Traction | DelveInsight

Calibr-Skaggs Institute for Innovative Medicines (Scripps Research) received FDA clearance for their IND application to study switchable CAR-T therapy (CLBR001 + SWI019) in autoimmune diseases. The upcoming Phase 1 trial will assess safety and efficacy in patients with myositis, systemic sclerosis, lupus,

More news about: DelveInsight Business Research, LLP

Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.